Jazz Pharmaceuticals, Inc. (JAZZ) Reports In-Line Q3 EPS; Guides Above the Street
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $246.81 -0.31%
Revenue Growth %: +7.1%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.1%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q3 EPS of $0.94, in-line with the analyst estimate of $0.94. Revenue for the quarter came in at $73.3 million versus the consensus estimate of $72.03 million.
Jazz Pharmaceuticals, Inc. sees FY2011 EPS of $3.45-$3.50, versus the consensus of $3.44.
Jazz Pharmaceuticals, Inc. sees FY2011 EPS of $3.45-$3.50, versus the consensus of $3.44.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Brady Corp. (BRC) Tops Q4 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
